Allogene Therapeutics (ALLO)
(Delayed Data from NSDQ)
$2.62 USD
-0.05 (-1.87%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $2.62 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ALLO 2.62 -0.05(-1.87%)
Will ALLO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ALLO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALLO
IGM Biosciences (IGMS) Surges 11.6%: Is This an Indication of Further Gains?
Allogene Therapeutics (ALLO) Up 6.4% Since Last Earnings Report: Can It Continue?
ALLO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Allogene (ALLO) Posts Narrower Than Expected Loss in Q2
Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates
Allogene Therapeutics (ALLO) Down 13.9% Since Last Earnings Report: Can It Rebound?
Other News for ALLO
Biotech Alert: Searches spiking for these stocks today
Cellectis: Cheap With Promising But Speculative Cancer Therapies
Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell Therapies
Buy Rating Affirmed for Allogene Therapeutics on Strong Financials and Positive Pipeline Prospects
Optimistic Outlook for Allogene Therapeutics with a Strong Buy Rating